CLAIMS

1. A pharmaceutical composition for increasing the number of platelets comprising a 2-acylaminothiazole derivative represented by the following general Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:



(I)

wherein symbols have the following meanings,

Ar^1: optionally substituted aryl, monocyclic aromatic heterocycle, or bicyclic condensed heterocycle (with the proviso that when R^1 is aryl or pyridyl, each of which may be substituted with one or more groups selected from the group consisting of lower alkyl, -CO-lower alkyl, -COO-lower alkyl, -OH, -O-lower alkyl, -OCO-lower alkyl, and halogen, and R^2 is a group represented by the following general Formula (II); Ar^1 is not phenyl or pyridyl, each of which may be substituted with one or more groups selected from the group consisting of lower alkyl, -CO-lower alkyl, -COO-lower alkyl, -OH, -O-lower alkyl, -OCO-lower alkyl, and halogen),

R^1: aryl or monocyclic aromatic heterocycle, each of which may be substituted,

R^2: a group represented by the following general Formula (II), (III) or (IV):



(II)



(III)



(IV)

wherein symbols have the following meanings,

n: an integer of 1 to 3,

m: an integer of 1 to 3,

(when n or m is an integer of 2 or more, $CR^{20}R^{21}$ and $CR^{22}R^{23}$ may be identical or different.)

X: O, S, or a group represented by $N\text{-}R^{26}$ or $C(\text{-}R^{27})\text{-}R^{28}$,

E, G, J, L: independently N or a group represented by $C\text{-}R^{29}$, with the proviso that at least one of them is $C\text{-}R^{29}$,

R^{20}, R^{21}, R^{22}, R^{23}, R^{26}, R^{27}, R^{28}, R^{29}: which may be identical or different, -H; -OH; -O-lower alkyl; optionally substituted lower alkyl; optionally substituted cycloalkyl; optionally substituted aryl; optionally substituted arylalkyl; optionally substituted aromatic heterocycle; optionally substituted aromatic heterocyclic alkyl; optionally substituted nonaromatic heterocycle; optionally substituted lower alkenyl; optionally substituted lower alkylidene; -COOH; -COO-lower alkyl; -COO-lower alkenyl; -COO-lower alkylene-aryl; -COO-lower alkylene-aromatic heterocycle; carbamoyl or amino, each of which may be substituted with one or more groups selected from the group consisting of lower alkyl and cycloalkyl, each of which may be substituted with halogen, -OH, -O-lower alkyl, or -O-aryl; -NHCO-lower alkyl; or oxo.

R^{24}, R^{25}: which may be identical or different, -H, optionally substituted lower alkyl, optionally substituted cycloalkyl, or optionally substituted nonaromatic heterocycle.

2. The pharmaceutical composition according to Claim 1, wherein R^1 is phenyl or thienyl, each of which may be substituted with 1 to 3 halogen atoms (when substituted with 2 or 3 halogen atoms, the halogen atoms may be identical or different); R^2 is a group represented by the general Formula (II) (wherein n is 2, m is 2, X is a group represented by N-R^{26} or C(-R^{27})-R^{28}); and Ar^1 is phenyl or pyridyl, each of which may be substituted.

3. The pharmaceutical composition according to Claim 1 or 2, wherein the pharmaceutical composition is used as a therapeutic agent for thrombocytopenia.

4. The pharmaceutical composition according to Claim 1 or 2, wherein the pharmaceutical composition is a c-Mpl ligand.

5. A 2-acylaminothiazole derivative represented by the following general Formula (V) or a pharmaceutically acceptable salt thereof:



(V)

wherein symbols have the following meanings:

Ar^2: a group represented by Ar^1 as described in Claim 1, with the

proviso that indol-2-yl is excluded,

R^3: a group represented by R^1 as described in Claim 1,

R^4: a group represented by R^2 as described in Claim 1, with the proviso that a group represented by the general Formula (IV) is excluded.

6. The compound according to Claim 5, wherein Ar^2 is phenyl or monocyclic aromatic heterocycle, each of which may be substituted.

7. The compound according to Claim 6, wherein R^3 is phenyl or thienyl, each of which may be substituted; R^4 is a group represented by the general Formula (II); Ar^2 is phenyl or pyridyl, each of which may be substituted.

8. The compound according to Claim 7, wherein n is 2, m is 2, and X is a group represented by N-R^{26} or C(-R^{27})-R^{28}.

9. The compound according to Claim 8, wherein R^3 is phenyl or thienyl, each of which may be substituted with 1 to 3 halogen atoms (when substituted with 2 or 3 halogen atoms, the halogen atoms may be identical or different.).

10. The compound according to Claim 9, wherein R^4 is 4-(piperidin-1-yl)piperidin-1-yl, 4-propylpiperidin-1-yl, 4-cyclohexylpiperazin-1-yl, or 4-propylpiperazin-1-yl.

11. The compound according to Claim 10, wherein Ar^2 is phenyl which is unsubstituted at 2- and 6-positions, substituted with –H, -F, -Cl, or –Br

at 3-position, substituted with -F, -Cl, or -Br at 5-position, and substituted at 4-position; or pyridin-3-yl which is unsubstituted at 2- and 4-positions, substituted with -F, -Cl, or -Br at 5-position, and substituted at 6-position.

12. The compound according to Claim 11, wherein Ar^2 is phenyl which is substituted at 4-position with a group selected from the group consisting of –O-R^Y, -NH-R^Y, optionally substituted piperidin-1-yl and optionally substituted piperazin-1-yl; or pyridin-3-yl which is substituted at 6-position with a group selected from the group consisting of –O-R^Y, -NH-R^Y, optionally substituted piperidin-1-yl and optionally substituted piperazin-1-yl (wherein R^Y is lower alkyl which may be substituted with one or more groups selected from the group consisting of –OH, -O-lower alkyl, amino which may be substituted with one or two lower alkyl, -CO_2H, -CO-lower alkyl, carbamoyl which may be substituted with one or two lower alkyl, cyano, aryl, aromatic heterocycle, nonaromatic heterocycle and halogen.).

13. The compound according to any one of Claims 5 to 12, wherein the compound is selected from the group consisting of:

N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide,

3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,

N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperidino)thiazol-2-yl]-2-

methoxyisonicotinamide,

N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]isoquinoline-6-carboxamide,

3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(3-hydroxypropoxy)nicotinamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[(3-hydroxypropyl)amino)]nicotinamide,

1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-cyanopiperidino)-3,5,-difluorobenzamide,

1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxylic acid,

1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-6-fluorophenyl)piperidin-4-carboxylic acid,

1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidin-4-carboxamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-hydroxymethylpiperidino)nicotinamide,

1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-

2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(3-trifluoromethylphenyl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(2-methoxyethyl)carbamoyl]piperidino}nicotinamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(3-methoxypropyl)carbamoyl]piperidino}nicotinamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[4-(morpholinocarbonyl)piperidino]nicotinamide, and

a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising the compound of any one of Claims 5 to 13 as an active ingredient.

15. The pharmaceutical composition according to Claim 14, wherein the pharmaceutical composition is used as an agent for increasing the number of platelets.

16. The pharmaceutical composition according to Claim 14, wherein the pharmaceutical composition is use as a therapeutic agent for thrombocytopenia.

17. The pharmaceutical composition according to Claim 14, wherein the pharmaceutical composition is a c-Mpl ligand.